Perspectives: The Government Should Utilize An Obscure Patent Provision To Lower Drug Prices

The New York Times: How The Government Can Lower Drug Prices
In Baltimore, the health commissioner, Dr. Leana Wen, uses a need-based algorithm to decide which emergency rooms, needle-exchange vans, E.M.T.s and opioid outreach workers receive the city’s limited supply of naloxone — and which don’t. The drug, which reverses overdoses, has saved some 14,000 Baltimore residents since 2015. But its price has increased in recent years, by between 95 and 500 percent, depending on which version of the medication is being considered. Even with donations and discounts from drug makers, Dr. Wen says the city can’t afford all the naloxone it needs. (6/20)

Roll Call: To Keep Drug Costs Low, Think Competition, Not Price Controls
Even in today’s highly partisan environment, there’s one thing nearly all Americans agree on: The soaring cost of prescription drugs is alarming. In fact, 80 percent of Americans consider the cost of prescription drugs unreasonable. At the same time, a majority of Americans recognize that prescription drugs have improved countless lives. The president’s recently unveiled comprehensive blueprint to lower prescription drug costs has many ideas worthy of exploration. However, if we truly want to reduce costs and make life-changing and life-saving medications accessible to all Americans, we must increase competition among prescription drugs — particularly new drugs that have the ability to cure diseases, but face limited competition. (Sen. Orrin G. Hatch, 6/25)

Vox: A Plan To Reduce Drug Prices That Could Unite Libertarians And Socialists
President Donald Trump and Secretary of Health and Human Services Alex Azar recently introduced American Patients First, a complicated plan intended to make prescription drugs more affordable. It includes many ideas and suggestions, such as requiring drug makers to put the list prices of their products in their advertisements and “working across the administration to assess the problem of foreign free-riding.” A few commentators think the plan will materially reduce prices, but we are skeptical. (Charles Silver and David A. Hyman, 6/21)

Forbes: Sticker Shock: The Real Cost Of America's 10 Most Expensive Drugs
The high price of pharmaceuticals has become a constant topic of conversation in the U.S. As medical costs rise, consumers face greater financial uncertainty. And day after day, both the White House and Congress make promises that they will lower prescription costs to alleviate constituent concerns, but few changes have backed up their words. That said, time and again we are reminded that despite the rising costs of pharma, the medical industry is exceptionally complex and very rarely do patients see the real price tag of their drugs. And that lack of information – not to mention the number of third-party entities that get involved – creates a confusing and frustrating, and often bloated, price structure. (Nicole Fisher, 6/26)